International, post-authorisation non-interventional study to evaluate real-life effectiveness, safety and utilisation patterns of Octapharma's FVIII concentrates Nuwiq, Octanate, and Wilate in previously untreated and minimally treated severe haemophilia A patients in routine clinical practice.
Protocol Amendment History
14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2018-10-03; most recent amendment 2026-05-29.